RB-601
Cancer (tumors expressing c-MET and EGFR)
Pre-clinicalActive
Key Facts
Indication
Cancer (tumors expressing c-MET and EGFR)
Phase
Pre-clinical
Status
Active
Company
About Radiance Biopharma
Radiance Biopharma is a private, pre-clinical stage biotech focused on pioneering next-generation Antibody Drug Conjugates (ADCs), with a lead candidate targeting c-MET and EGFR. The company has secured exclusive rights to a key technology platform and is actively engaging with the investment community. Its strategy centers on developing highly targeted therapies for broad cancer indications using novel antibody formats and tumor-specific targets like membrane Hsp70.
View full company profile